



Recurrent TET2 mutations in adult T cell leukemia

Ambroise Marçais, Katia Hanssens, Lucy Cook, Thomas Mercher, Philippe Gaulard, Vahid Asnafi, Claudine Pique, Ali Bazarbachi, Felipe Suarez, Olivier Bernard, et al.

► To cite this version:

Ambroise Marçais, Katia Hanssens, Lucy Cook, Thomas Mercher, Philippe Gaulard, et al.. Recurrent TET2 mutations in adult T cell leukemia. *Retrovirology*, 2014, 11 (Suppl 1), pp.P119. inserm-00924970


HAL Id: inserm-00924970

<https://www.hal.inserm.fr/inserm-00924970>

Submitted on 7 Jan 2014

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



POSTER PRESENTATION

Open Access

Recurrent TET2 mutations in adult T cell leukemia

Ambroise Marçais^{1*}, Katia Hanssens², Lucy Cook³, Thomas Mercher⁴, Philippe Gaulard⁵, Vahid Asnafi⁶, Claudine Pique⁷, Ali Bazarbachi⁸, Felipe Suarez¹, Olivier Bernard⁴, Charles RM Bangham³, Patrice Dubreuil², Olivier Hermine¹

From 16th International Conference on Human Retroviruses: HTLV and Related Viruses
Montreal, Canada. 26-30 June 2013

Deregulation of DNA methylation has been recently identified in malignant hematologic diseases such as inactivation of the Ten-ElevenTranslocation 2 (TET2) gene by haplo-insufficiency. Inactivating mutations of TET2 were first described in myeloid disorders and more recently in peripheral T-cell lymphomas especially those that are harboring T follicular helper features like angio-immunoblastic T cell lymphoma. In order to determine new oncogenic pathways in Adult T cell leukemia/lymphoma (ATLL) that could cooperate with viral oncogenic proteins, we investigated the presence of TET2 coding sequence mutations and their clinical relevance in a retrospective cohort of 49 ATL patients. We identify inactivating mutations of TET2 gene in 10 patients of 49 analyzed (20%). Of the 37 patients with aggressive forms (acute and lymphoma), 9 (24%) had TET2 mutations as only one (8%) of the 12 with indolent forms had a TET2 mutation. This last patient had nevertheless a poor outcome and died four years from the diagnosis from relapse. In addition, five patients show the same recurrent point mutation, which conducts to the loss of coding sequence in one allele and lead to haplo-insufficiency. Analysis of different clinical cases suggests that TET2 mutation could be acquired at different steps of the T cell oncogenesis and could even in some cases precede HTLV-1 infection. Analysis of viral integration is still ongoing. Here, we show that loss of TET2 is frequently associated with ATLL and seems to more frequent in aggressive forms.

Authors' details

¹Service d'Hématologie, Hôpital Universitaire Necker, Université René Descartes, Institut Imagine, Paris, France. ²Inserm U1068, Centre de

Recherche en Cancérologie de Marseille, Institut Paoli-Calmettes, Université de la Méditerranée, Marseille, France. ³Department of Immunology, Wright-Fleming Institute, Imperial College, London, UK. ⁴Inserm U985, Institut Gustave Roussy, Université Paris-Sud 11, Villejuif, France. ⁵Département de Pathologie, Groupe Henri Mondor Albert Chenevier, Créteil, France. ⁶Département d'Hématologie, Hôpital Universitaire Necker, Université René Descartes, Paris, France. ⁷Inserm, U1016, Institut Cochin, Paris, France. ⁸Department of Internal Medicine, American University of Beirut, Beirut, Lebanon.

Published: 7 January 2014

doi:10.1186/1742-4690-11-S1-P119

Cite this article as: Marçais et al.: Recurrent TET2 mutations in adult T cell leukemia. *Retrovirology* 2014 **11**(Suppl 1):P119.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

